NovaBridge Biosciences (NBP) Total Non-Current Liabilities (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Total Non-Current Liabilities for 7 consecutive years, with $29.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 152.34% year-over-year to $29.1 million; the TTM figure through Dec 2025 stood at $29.1 million (up 152.34% YoY), while the FY2025 annual figure was $29.1 million, up 152.34% from the prior year.
• Total Non-Current Liabilities grew to $29.1 million in Q4 2025 per NBP's latest filing, from $11.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $145.0 million in Q2 2023 and bottomed at $11.5 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $54.3 million across 5 years, with a median of $33.7 million in 2022.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 1572.79% — and 2024, when it plunged 76.29%.
• NovaBridge Biosciences' Total Non-Current Liabilities stood at $27.6 million in 2021, then rose by 18.25% to $32.6 million in 2022, then surged by 48.89% to $48.6 million in 2023, then slumped by 76.29% to $11.5 million in 2024, then surged by 152.34% to $29.1 million in 2025.
• Business Quant data shows NBP's Total Non-Current Liabilities at $29.1 million in Q4 2025, $11.5 million in Q4 2024, and $48.6 million in Q4 2023.